

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

Claim 1. (Original) A method for inducing or modulating T or B cell tolerance to donor cells, tissue or organ in a recipient comprising administering to the recipient a LFA-1 inhibitor in combination with a costimulation inhibitor and/or a mTOR inhibitor.

Claim 2 (Original) A method for inducing hematopoietic chimerism in a recipient of cells, tissue or organ transplant from a donor comprising administering to the recipient

- i) bone marrow cells or other precursor cells from the donor; and
- ii) a LFA-1 inhibitor in combination with at least one co-agent selected from a costimulation inhibitor and a mTOR inhibitor.

Claim 3 (Original) A method for treating diabetes comprising administering to a subject in need of such treatment, in addition to i) and ii) as defined in claim 2,

- iii) allogeneic pancreatic islet cells or other insulin producing cells.

Claim 4 (Original) A method for inducing apoptosis of activated T cells in a subject in need of such treatment, comprising administering to said subject a therapeutically effective amount of a LFA-1 inhibitor in combination with at least one co-agent selected from a costimulation inhibitor and a mTOR inhibitor.

Claim 5 (Original) A method for delaying progression of, attenuating severity of, suppressing, mitigating or treating immune disorders or diseases in a subject by inducing or modulating immune tolerance in said subject, the immune disorders or diseases being dependent on activation of lymphoid cells, which method comprises administering to said subject a therapeutically effective amount of a LFA-1 inhibitor in combination with at least one co-agent selected from a costimulation inhibitor and a mTOR inhibitor.

Claim 6 (Original) A method for treating malignancies in a subject in need thereof, comprising administering to said subject cells i) and a product ii) as defined in claim 2, in order to achieve full or mixed hematopoietic chimerism.

Claim 7 (Original) A method for treating non-malignant diseases of bone marrow failure, comprising administering to said subject cells i) and a product ii) as defined in claim 2, in order to achieve full or mixed hematopoietic chimerism.

Claim 8 (Currently amended) A method according to ~~any preceding claim 1~~, further comprising administering to the recipient or subject 15-deoxyspergualine or an immunosuppressive homologue, analogue or derivative thereof.

Claim 9 (Currently amended) Use of a LFA-1 inhibitor in combination with at least one co-agent selected from a costimulation inhibitor and a mTOR inhibitor in a method according to ~~any one of claims 1 to 8~~.

Claim 10 (Original) A pharmaceutical combination comprising

- a) a LFA-1 inhibitor; and
- b) at least one co-agent selected from a costimulation inhibitor and a mTOR inhibitor.

Claim 11 (Currently amended) A combination ~~according to claim 10 comprising~~

- a) a LFA-1 inhibitor; and
- b) at least one co-agent selected from a costimulation inhibitor and a mTOR inhibitor  
for use in a method according to ~~any one of claims 1 to 8~~.

Claim 12 (Currently amended) A combination according to claim 10 or ~~claim 11~~, further comprising 15-deoxyspergualine or an immunosuppressive homologue, analogue or derivative thereof.